论文部分内容阅读
目的观察舒利迭治疗稳定期慢性阻塞性肺疾病(COPD)的可行性及安全性。方法将我院116例患者随机分成两组:对照组54例采用常规传统治疗方法,即口服茶碱缓释片、祛痰剂;治疗组62例在传统治疗的基础上加用舒利迭吸入治疗。2组治疗前后行肺功能、6min步行距离(6MWD)检测,详细观察并记录临床症状体征变化及药物不良反应。结果治疗组治疗后的临床症状及体征评分、动脉血气分析、肺功能及6MWD均明显改善(P<0.05),与对照组治疗后比较,差异均具有显著性(P<0.05)。治疗组有2例出现口干、咽部不适,加强漱口后逐渐缓解;1例出现心悸,心率l10～1160次/min,平静休息后自行缓解。未见其他明显不良反应。结论舒利迭可改善Ⅲ～Ⅳ级稳定期COPD患者临床症状,增强肺功能,对其血气分析指标有明显的改善作用。
Objective To observe the feasibility and safety of seretide in the treatment of stable chronic obstructive pulmonary disease (COPD). Methods One hundred and sixty-six patients in our hospital were randomly divided into two groups: control group (n = 54) received conventional therapies, ie oral theophylline sustained-release tablets and expectorant; in the treatment group, 62 patients were treated with seretide treatment. Before and after treatment, pulmonary function was measured in 2 groups and 6MWD in 6min. The changes of clinical symptoms and signs and adverse drug reactions were observed and recorded in detail. Results After treatment, the clinical symptoms and signs, arterial blood gas analysis, lung function and 6MWD were significantly improved in the treatment group (P <0.05). Compared with the control group after treatment, the differences were significant (P <0.05). The treatment group had 2 cases of dry mouth and pharynx discomfort, and gradually alleviated after gargling; 1 case had heart palpitations, heart rate l10 ~ 1160 beats / min, rest after calm relief. No other obvious adverse reactions. Conclusion Seretide can improve the clinical symptoms of stage Ⅲ ~ Ⅳ stable COPD patients and enhance pulmonary function, which can obviously improve the blood gas analysis indexes.